EcoDrugPlus

Neuropeptide Y Receptor Y5

Ensembl ID : ENSOCUG00000027192
Gene Symbol: NPY5R
2 Cross references
135 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSOCUG00000010696
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOCUG00000009736
Gene Symbol: NTRK2
3 Cross references
286 Possible Orthologues:

Nicastrin

Ensembl ID : ENSOCUG00000014503
Gene Symbol: NCSTN
2 Cross references
203 Possible Orthologues:

Nischarin

Ensembl ID : ENSOCUG00000007987
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSOCUG00000001903
Gene Symbol: NOS2
2 Cross references
163 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSOCUG00000022014
Gene Symbol: NOTCH3
2 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSOCUG00000021712
Gene Symbol: NFKB1
2 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSOCUG00000005735
Gene Symbol: NFKB2
2 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSOCUG00000007177
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOCUG00000011676
Gene Symbol: NR3C1
2 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSOCUG00000003137
Gene Symbol: NR3C2
2 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).